Piper Sandler analyst Joseph Catanzaro raised the firm’s price target on Biomea Fusion (BMEA) to $19 from $10 and keeps an Overweight rating on the shares. The firm notes Biomea reported Q3 earnings and provided a pipeline update. Most notably, Biomea is now specifically guiding towards Phase II topline readouts in both T2D and T1D in December.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMEA: